• Niagen Bioscience (NAGE) is a leader in healthy aging research.
• NAGE has a 100% technical “Buy” signal and is trading above its moving averages. 
• Shares have gained 170% over the past year.
• Revenue is expected to grow 23.49% this year, with earnings increasing 8.05%.

Today’s Featured Stock:

Valued at $766 million, Niagen Bioscience (NAGE) is a leader in nicotinamide adenine dinucleotide science. The company focuses on researching healthy aging. 

What I’m Watching:

I found today’s Chart of the Day by using Barchart’s powerful screening functions. I sorted for stocks with the highest technical buy signals, superior current momentum in both strength and direction, and a Trend Seeker “Buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. NAGE checks those boxes.

NAGE Price vs. Daily Moving Averages:

Barchart Technical Indicators for NAGE:

Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

When a stock is trading above all of its daily moving averages and is only 2.9% from its 52-week high, it won’t take much to hit another new high.

• NAGE has a 100% technical “Buy” signal.
• The stock closed at $9.71 on May 13 above its 50-week moving average of $7.39.
• NAGE has a Weighted Alpha of +103.70.
• The stock has gained 170% over the past year.
• Trend Seeker “Buy” signal intact.
• NAGE is trading above its 20, 50 and 100-day moving averages.
• The stock has made 17 new highs and is up 61% in the last month.
• The 14-day Relative Strength Index is at 72.75%.
• The technical support level is at $9.11.

Follow the Fundamentals:

• $766 million market cap.
• 99.44x price-earnings ratio.
• Revenue is expected to grow 23.49% this year and another 21.41% next year.
• Earnings are estimated to increase 160% this year and another 69% next year.

Analyst and Investor Sentiment on NAGE:

I don’t buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it’s hard to make money swimming against the tide.

It looks like not only Wall Street analysts, but also many of the popular investing advisory services, have mixed feelings on this stock.

• Wall Street analysts tracked by Barchart issued 3 “Strong Buy” opinions on the stock with an average price target of $9.70.
• Value Line gives the stock an average rating. 
• CFRA’s MarketScope gives the stock a “Strong Buy” rating.
• MorningStar thinks the stock is 25% over valued. 
• 5,730 investors monitor the stock on Seeking Alpha, which rates the stock a “Hold.”

The Bottom Line:

Currently Niagen Biosciences is a leader in the longevity supplement sector, has momentum and support from both the market and individual investors, and seems to be beating out its competition from rivals Elysium Health, Life Extension, and Thorne Research.

Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.